Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 19/20 | 0.47 |
| ▸ | CDK2 | P24941 | 19/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 17/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6971324 | 1.00 | MAPK8 (1.00) | MAPK8CCNE1CDK2CCNE2 | |
| SCHEMBL14040855 | 0.98 | MAPK8 (0.96) | MAPK8CCNE1CDK2CCNE2 | |
| SCHEMBL13198013 | 0.90 | MAPK8 (0.81) | MAPK8CCNE1CDK2CCNE2 | |
| SCHEMBL6958386 | 0.88 | MAPK8 (0.78) | MAPK8CCNE1CDK2CCNE2 | |
| SCHEMBL6958391 | 0.88 | MAPK8 (0.78) | MAPK8CCNE1CDK2CCNE2 | |
| SCHEMBL6965314 | 0.87 | MAPK8 (0.77) | MAPK8CCNE1CDK2CCNE2 | |
| SCHEMBL6965328 | 0.87 | MAPK8 (0.77) | MAPK8CCNE1CDK2CCNE2 | |
| SCHEMBL13207561 | 0.87 | MAPK8 (0.76) | MAPK8CCNE1CDK2CCNE2 | |
| SCHEMBL6969422 | 0.86 | MAPK8 (0.75) | MAPK8CCNE1CDK2CCNE2 | |
| SCHEMBL6968404 | 0.86 | MAPK8 (0.75) | MAPK8CCNE1CDK2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750033-B2 | Preventive and remedy for collagen or elastin metabolic disorder | YAMAGUCHI UNIVERSITY (JP) | 2010-07-06 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20070248944-A1 | Preventive and Remedy for Collagen or Elastin Metabolic Disorder | YAMAGUCHI UNIVERSITY (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1149092-B1 | 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES | HOFFMANN LA ROCHE (CH) | 2003-10-29 | — | — | EP | disclosed |
| US-6313310-B1 | JUN N-TERMINAL KINASE (JNK) ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC ARTHRITIS AND NEURO-DEGENERATIVE DISEASE TREATMENT | HOFFMANN-LA ROCHE INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1149092-A2 | 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000035906-A2 | 4- AND 5-ALKYNYLOXINDOLES AND 4- AND 5-ALKENYLOXINDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | MAPK8 40/4885CCNE1 1203/4885CDK2 176/4885 |
| US-20070248944-A1 | Preventive and Remedy for Collagen or Elastin Metabolic Disorder | COLGALT1, COL2A1, COL14A1 | MAPK8 39/4885CCNE1 3186/4885CDK2 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.